Physician profile
Ruby D Saulog
NPI 1033193677
$6,924.70
in general payments reported to CMS, 2019-2025
34 companies · $223 in 2025
The $223 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,117 · 2020: $1,059 · 2021: $1,889 · 2022: $1,660 · 2023: $761 · 2024: $217 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $2,133.94 | 2019-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $564.77 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $503.49 | 2020-2023 | |
| Otsuka America Pharmaceutical, INC. | $448.00 | 2019-2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $310.09 | 2019-2023 | |
| Harmony Biosciences LLC | $287.46 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $219.27 | 2019-2021 | |
| Ucb, INC. | $204.21 | 2019-2023 | Briviact |
| Takeda Pharmaceuticals U.S.A., INC. | $191.87 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $188.90 | 2020-2022 | |
| Biogen, INC. | $184.17 | 2019-2023 | Tysabri, Vumerity |
| Kyowa Kirin, INC. | $180.95 | 2020-2022 | |
| Abbvie INC. | $162.08 | 2019-2023 | Ubrelvy |
| Supernus Pharmaceuticals, INC. | $148.88 | 2019-2022 | |
| Alkermes, INC. | $146.77 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $130.84 | 2019-2022 | |
| Genentech USA, INC. | $86.45 | 2019-2022 | |
| Lundbeck LLC | $82.95 | 2019-2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $64.84 | 2022 | |
| Ironshore Pharmaceuticals INC. | $59.25 | 2022-2023 | Jornay Pm |
| Sk Life Science, INC. | $58.46 | 2021-2022 | |
| Allergan, INC. | $57.43 | 2020 | |
| Acorda Therapeutics, INC | $56.57 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $51.40 | 2019-2022 | |
| Emd Serono, INC. | $50.77 | 2019 | |
| Pfizer INC. | $49.57 | 2023 | |
| Mdd US Operations, LLC | $47.89 | 2019 | |
| Genzyme Corporation | $45.02 | 2019-2021 | |
| Lilly USA, LLC | $44.22 | 2020-2023 | Reyvow, Emgality |
| Avanir Pharmaceuticals, INC. | $43.92 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $41.85 | 2021 | |
| Celgene Corporation | $31.58 | 2022 | |
| Fisher & Paykel Healthcare INC | $29.38 | 2023 | Fisher & Paykel Healthcare |
| Biohaven Pharmaceuticals, INC. | $17.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Saulog listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.